Compare Krispy Kreme Inc (DNUT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Viatris Inc — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $508.36M), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 39.6× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Viatris Inc for 57 Days on average.
| DNUT | VTRS | |
|---|---|---|
Market Cap | $508.36M | $20.12B |
Volume | 1,955,706 | 7,543,511 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $18.27 |
52-Week Low | $2.87 | $9.74 |
Typical Hold Time | 45 Days | 57 Days |
Enterprise Value | $1.75B | $32.24B |
Dividend Yield | 3.47% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, down 0.33% on the day, with a bearish technical signal. The company reported a net loss of $515.77 million in 2025, despite a 75.19% gross margin, and faces legal investigations into fiduciary duties. Revenue declined to $1.52 billion in 2025 from $1.7 billion in 2024.
The outlook is cautious due to persistent losses and legal overhangs, though analyst consensus leans buy. Key risks include profitability challenges and high debt. Upside depends on operational turnaround and new product launches driving growth.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
